Spago Nanomedical AB (SPAG) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Flat results in Mar 25

INTEREST(9M) At SEK 0.12 MM has Grown at inf%
ROCE(HY) Lowest at -107.53%

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 56 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.91

Return on Equity

-230.65%

Price to Book

4.52

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

-7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-41.07%

6 Months

-22.46%

1 Year

-12.55%

2 Years

-38.3%

3 Years

-77.05%

4 Years

-96.02%

5 Years

0.0%

Spago Nanomedical AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

13.46%

EBIT Growth (5y)

-15.74%

EBIT to Interest (avg)

-38.27

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.04

Sales to Capital Employed (avg)

0.05

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.81

EV to EBIT

-2.47

EV to EBITDA

-2.49

EV to Capital Employed

89.42

EV to Sales

58.79

PEG Ratio

Dividend Yield

ROCE (Latest)

-3615.50%

ROE (Latest)

-166.75%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -66.67% vs -50.00% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 5.41% vs 5.13% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.30",
          "chgp": "-66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.10",
          "val2": "-8.30",
          "chgp": "2.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.00",
          "val2": "-7.40",
          "chgp": "5.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-100,530.90%",
          "val2": "-24,896.40%",
          "chgp": "-7,563.45%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 58.33% vs 9.09% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 22.99% vs 1.63% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.90",
          "val2": "1.20",
          "chgp": "58.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-38.10",
          "val2": "-47.00",
          "chgp": "18.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-32.50",
          "val2": "-42.20",
          "chgp": "22.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-20,084.20%",
          "val2": "-39,262.70%",
          "chgp": "1,917.85%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.10

0.30

-66.67%

Operating Profit (PBDIT) excl Other Income

-8.10

-8.30

2.41%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-7.00

-7.40

5.41%

Operating Profit Margin (Excl OI)

-100,530.90%

-24,896.40%

-7,563.45%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -66.67% vs -50.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 5.41% vs 5.13% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

1.90

1.20

58.33%

Operating Profit (PBDIT) excl Other Income

-38.10

-47.00

18.94%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-32.50

-42.20

22.99%

Operating Profit Margin (Excl OI)

-20,084.20%

-39,262.70%

1,917.85%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 58.33% vs 9.09% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 22.99% vs 1.63% in Dec 2023

All Annual Results

Company CV

About Spago Nanomedical AB

Spago Nanomedical AB

Pharmaceuticals & Biotechnology

Spago Nanomedical publ AB, formerly Spago Imaging publ AB, is a Sweden-based biotechnology company. It specialized in the areas of contrast agents and nanoscale life science research. The Company is involved in three projects: Spago Pix, a nanomaterial developed for use as a cancer selective contrast agent for Magnetic Resonance Imaging (MRI); the therapeutic project Tumorad, using nanoparticles loaded with radionuclides for selective treatment of cancers, which are unsuitable for surgery or external radiation; and Archaea Platin, aimed at delivering of chemotherapeutic substance cisplatin selectively to tumors in order to reduce side effects on healthy tissue. The Company's technology comprises a technology platform IonXgel, which is a nano-sized biocompatible material consisting of polar polymers; a protein-based drug delivery platform, ProtRc; and 3PEG, a platform which enables attachment of polyethylene glycol (PEG) derivatives to small molecules (PEGylation).

Company Coordinates

Company Details

Scheelevagen 22 , LUND None : 223 63

Tel: 46 46 81188

http://spagonanomedical.se

Registrar Details